CIK 0001357459 · Non-accelerated filer<br>Smaller reporting company
PALISADE BIO, INC.
Sign in to watch- Ticker
- PALI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 522007292
- Phone
- (858) 704-4900
- Business address
- 7750 EL CAMINO REAL, SUITE 5200, CARLSBAD, CA, 92009
- Former names
- PALISADE BIO, INC., Seneca Biopharma, Inc., Neuralstem, Inc.
- Open-market buys, last 90 days
- $28,800
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$28,800. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-06 | Jones Mitchell Lawrence Chief Medical Officer | Option exercise · Restricted Stock Units | −4,558 | 45,586 | ||
| 2024-02-06 | Jones Mitchell Lawrence Chief Medical Officer | Option exercise · Restricted Stock Units | −2,333 | 25,667 | ||
| 2024-02-06 | Finley John David CEO, CFO, Director | Option exercise | +3,475 | 88,124 | ||
| 2024-02-06 | Finley John David CEO, CFO, Director | Option exercise | +3,167 | 91,291 | ||
| 2024-02-06 | Finley John David CEO, CFO, Director | Option exercise · Restricted Stock Units | −3,475 | 27,800 | ||
| 2024-02-06 | Finley John David CEO, CFO, Director | Option exercise · Restricted Stock Units | −3,167 | 34,833 | ||
| 2024-02-06 | Finley John David CEO, CFO, Director | Purchase | +10,000 | $0.47 | $5K | 84,649 |
| 2024-01-31 | Finley John David CEO, CFO, Director | Purchase | +10,000 | $0.56 | $6K | 74,649 |
| 2024-01-31 | Williams Donald Allen Director | Purchase | +10,000 | $0.61 | $6K | 30,000 |
| 2024-01-03 | Finley John David CEO, CFO, Director | Option exercise | +1,309 | 64,649 | ||
| 2024-01-03 | Finley John David CEO, CFO, Director | Option exercise · Restricted Stock Units | −1,309 | 0 | ||
| 2023-12-11 | Finley John David CEO, CFO, Director | Option exercise | +5,559 | 63,340 | ||
| 2023-12-11 | Finley John David CEO, CFO, Director | Option exercise · Restricted Stock Units | −5,559 | 55,583 | ||
| 2023-11-21 | Diaz Stephanie Director | Grant or award · Restricted Stock Units | +5,820 | 5,820 | ||
| 2023-11-21 | Diaz Stephanie Director | Grant or award · Common Stock Options | +6,880 | 6,880 | ||
| 2023-11-21 | Trenschel Robert J. Director | Grant or award · Restricted Stock Units | +5,820 | 5,820 | ||
| 2023-11-21 | Trenschel Robert J. Director | Grant or award · Common Stock Options | +6,880 | 6,880 | ||
| 2023-11-21 | Jones Mitchell Lawrence Chief Medical Officer | Grant or award · Restricted Stock Units | +28,000 | 28,000 | ||
| 2023-11-21 | Jones Mitchell Lawrence Chief Medical Officer | Grant or award · Common Stock Options | +33,160 | 33,160 | ||
| 2023-11-21 | Finley John David CEO, CFO, Director | Grant or award · Restricted Stock Units | +38,000 | 38,000 |
Page 8 of 12 · 233 trades